BioNexus Gene Lab (BGLC) Long-Term Investments (2018 - 2026)

BioNexus Gene Lab (BGLC) has 9 years of Long-Term Investments data on file, last reported at $2.0 million in Q1 2026.

• For the quarter ending Q1 2026, Long-Term Investments rose 67.18% year-over-year to $2.0 million; the trailing twelve-month figure through Mar 2026 stood at $2.0 million (up 67.18% YoY), and the FY2025 full-year result was $2.0 million, up 60.26% from the prior year.
• Long-Term Investments steadied at $2.0 million in Q1 2026, from $2.0 million in the prior quarter.
• In the past five years, Long-Term Investments ranged from a high of $2.0 million in Q1 2026 to a low of $237760.0 in Q3 2025.
• A 5-year average of $1.4 million and a median of $1.2 million in 2025 frame the typical range for Long-Term Investments.
• Across the five-year window, Long-Term Investments surged 68.97% in 2022 and sank 88.08% in 2025, its largest moves.
• Tracing BGLC's Long-Term Investments over 5 years: stood at $1.2 million in 2022, then jumped by 47.7% to $1.7 million in 2023, then declined by 25.57% to $1.3 million in 2024, then jumped by 60.26% to $2.0 million in 2025, then climbed by 0.05% to $2.0 million in 2026.
• Business Quant data shows BGLC's Long-Term Investments at $2.0 million in Q1 2026, $2.0 million in Q4 2025, and $237760.0 in Q3 2025.